(redirected from Noradrenaline reuptake inhibitor)
Also found in: Medical.
NARINational Association of the Remodeling Industry
NARINational Agricultural Research Institute (various locations)
NARINational Ageing Research Institute
NARINorAdrenaline Reuptake Inhibitor
NARINational Affordable Rental Incentive (Australia)
NARINational Association for Resource Improvement (Bangladesh)
References in periodicals archive ?
(1987) and Fernandez-Pardal and Hilakivi (1989) found that the neonatal administration with desipramine (DMI, a selective noradrenaline reuptake inhibitor) was involved to a subsequent lengthening in immobility in the swim test, same results were found with zimelidine (ZMI, a selective serotonin reuptake inhibitor).
Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disorders.
Since serotonin is known as the "hormone of happiness", it is logical to think that selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors/selective noradrenaline reuptake inhibitors (SNRI) could be useful in the management of menopausal symptoms.
Thus, both type of antidepressants: the noradrenaline reuptake inhibitors (reboxetine, atomoxetine), and the serotonin-noradrenaline reuptake inhibitor (duloxetine), improved the recognition memory, while the tricyclic antidepressants (desipramine, mianserin) or the serotonin reuptake inhibitors (paroxetine, citalopram) did not significant influence the recognition memory in various behavioural models in rats (5).
Several treatment algorithms have been designed for the treatment of neuropathic pain, the important ones being those from Jensen et al,18 the EFNS14 and Dworkin et al.19 All three algorithms recommend a-2-d agonist (gabapentin, pregabalin), tricyclic antidepressants (TCAs), and Selective serotonin noradrenaline reuptake inhibitors (SNRIs###venlafaxine, and duloxetine) as first-line treatments and support opioid analgesics and tramadol as second-line treatments.
Current antidepressant drug therapies include selective serotonin reuptake inhibitors, serotonin and noradrenaline reuptake inhibitors and the older, less specific monoamine regulating drugs.
Current leading guidelines from the American Psychiatric Association (APA) and the Canadian Network for Mood and Anxiety Treatments (CANMAT) recommend selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors (SNRIs), as a first-line treatment for depression.
More promising results have been demonstrated with Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs) such as Duloxetine.